Table 3.
NFAT‐regulated cytokine expression and Tac concentrations among patients with and without viremia
| 1 week post‐Tx | 6 weeks post‐Tx | |||
|---|---|---|---|---|
| Viraemia a | Yes (n = 1) | No (n = 28) | Yes (n = 2) | No (n = 22) |
| RGE, % | 2.5 | 18.5 (1.5–68.7) | 24.0 (15.5–32.5) | 45.3 (5.7–76.2) |
| E 0 | 0.596 | 1.28 (0.029–3.90) | 0.50 (0.22–0.78) | 2.11 (0.22–4.99) |
| E 1.5 | 0.015 | 0.14 (0.001–1.37) | 0.14 (0.033–0.25) | 0.97 (0.023–2.52) |
| Tac C 0 | 5.2 | 5.0 (2.5–10.6) | 5.4 (4.3–6.4) | 5.9 (3.5–9.3) |
| Tac C 1.5 | 16.4 | 10.3 (3.5–33.4) | 6.9 (6.7–7.0) | 8.7 (5.0–18.7) |
| Tac doses, mg kg –1 day –1 | 0.11 | 0.064 (0.024–0.16) | 0.059 (0.042–0.075) | 0.054 (0.020–0.107) |
E0, gene expression before dosing; E1.5, gene expression 1.5 h after dosing; RGE, residual gene expression; Tac C0, predose tacrolimus concentrations; Tac C1.5, tacrolimus concentrations 1.5 h postdose; Tx, transplantation
a
Polyoma virus viraemia defined as BK or JC virus levels ≥10 000 DNA copies ml–1 in whole blood. Measurements were performed at the closest sampling period preceding the viraemia